Walleye Capital LLC Invests $68,000 in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Walleye Capital LLC acquired a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,706 shares of the biotechnology company’s stock, valued at approximately $68,000.

Other large investors have also modified their holdings of the company. Catalyst Funds Management Pty Ltd boosted its stake in shares of Aldeyra Therapeutics by 2,083.3% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,500 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth $69,000. SG Americas Securities LLC boosted its stake in shares of Aldeyra Therapeutics by 14.4% during the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 2,822 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Aldeyra Therapeutics by 62.7% during the 4th quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 9,178 shares in the last quarter. Finally, Boston Financial Mangement LLC acquired a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth $141,000. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Trading Up 0.4 %

NASDAQ ALDX opened at $2.66 on Monday. The company has a market capitalization of $158.83 million, a PE ratio of -2.83 and a beta of 0.94. Aldeyra Therapeutics, Inc has a 1-year low of $1.14 and a 1-year high of $7.20. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm’s fifty day simple moving average is $4.76 and its 200-day simple moving average is $5.05.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). As a group, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on ALDX. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, April 4th. BTIG Research dropped their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, April 7th.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company’s stock, valued at $8,343,708.42. This represents a 36.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.50% of the company’s stock.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.